177785-41-0

Basic information

• Product Name: 4-Amino-N-cyclopropylbenzene-1-sulfonamide
• Synonyms: N-Cyclopropyl 4-Aminophenylsulfonamide;4-Amino-N-cyclopropylbenzene-1-sulfonamide
• CAS NO: 177785-41-0
• Molecular Formula: C9H12N2O2S
• Molecular Weight: 212.27
• Product Categories: Acids and Derivatives;Amines and Anilines
• Mol File: 177785-41-0.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 401°C at 760 mmHg
• Flash Point: 196.3°C
• Appearance: /
• Density: 1.39g/cm³
• Vapor Pressure: 1.22E-06mmHg at 25°C
• Refractive Index: 1.637
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-Amino-N-cyclopropylbenzene-1-sulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Amino-N-cyclopropylbenzene-1-sulfonamide(177785-41-0)
• EPA Substance Registry System: 4-Amino-N-cyclopropylbenzene-1-sulfonamide(177785-41-0)

Safety Data

• Hazardous Substances Data: 177785-41-0(Hazardous Substances Data)

Usage

General Description

4-Amino-N-cyclopropylbenzene-1-sulfonamide is a chemical compound with the molecular formula C9H10N2O2S. It is a sulfonamide derivative containing an amino group and a cyclopropyl ring attached to a benzene ring. 4-Amino-N-cyclopropylbenzene-1-sulfonamide is a potential drug candidate and is being researched for its potential use as an antibacterial or antifungal agent. The presence of the sulfonamide group suggests that it may act as an inhibitor of enzymes involved in folate synthesis, making it potentially useful in the treatment of various bacterial and fungal infections. Further studies are needed to explore its biological activity and potential therapeutic uses.

InChI:InChI=1/C9H12N2O2S/c10-7-1-5-9(6-2-7)14(12,13)11-8-3-4-8/h1-2,5-6,8,11H,3-4,10H2

Upstream product

• 549476-61-1 N-cyclopropyl-4-nitrobenzenesulfonamide 
• 765-30-0 Cyclopropylamine 
• 98-74-8 4-Nitrobenzenesulfonyl chloride 

Relevant articles and documents

Synthesis and biological evaluation of norcantharidin derivatives as protein phosphatase-1 inhibitors

Cantharidin and norcantharidin display anticancer activity against a broad range of tumor cell lines. In this study, we have synthesized a series of norcantharidin derivatives and evaluated their cytotoxic effects on four human tumor cell lines together with the genetically normal human diploid fibroblast line WI-38. One of our compounds (1S,4R)-3-((4-(4-(4-fluorophenyl)piperazin-1-ylsulfonyl) phenyl)carbamoyl)-7-oxa-bicyclo[2.2.1]heptane-2-carboxylic acid (12) exhibited potent cytotoxic effects on the tumor cell lines A-549, HepG2, HeLa, and HCT-8, whereas it was less toxic to WI-38 cells than its parent compound, norcantharidin. In addition, this compound inhibited protein phosphatase-1 activity and microtubule formation in HeLa cells, and it also interacts with calf thymus DNA.

Synthesis and SAR of novel, 4-(phenylsulfamoyl)phenylacetamide mGlu 4 positive allosteric modulators (PAMs) identified by functional high-throughput screening (HTS)

Herein we disclose the synthesis and SAR of a series of 4-(phenylsulfamoyl)phenylacetamide compounds as mGlu4 positive allosteric modulators (PAMs) that were identified via a functional HTS. An iterative parallel approach to these compounds culminated in the discovery of VU0364439 (11) which represents the most potent (19.8 nM) mGlu4 PAM reported to date.

IMIDAZO[1,2-A]PYRIDINE AND PYRAZOLO[2,3-A]PYRIDINE DERIVATIVES

A compound of formula (I) wherein Ring A is imidazol[1,2a]pyrid-3-yl or pyrazolo[2,3a]pyrid-3-yl; Ris as defined within; m is 0-5; wherein the values of Rmay be the same or different; Ris as defined within; n is 0 to 2, wherein the values of Rmay be the same or different; Ring B is phenyl or phenyl fused to a C5-7cycloalkyl ring; Ris as defined within; p is 0-4; wherein the values of Rmay be the same or different; Ris as defined within; q is 0-2; wherein the values of Rmay be the same or different; and wherein p+q=5; or a pharmaceutically acceptable salt or an in vivo hydrolyzable ester thereof is described. The use of compounds of formula (I) in the inhibition of cell cycle kinases CDK2, CDK4, and CDK6 are also described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are detailed.